ChemicalBook
Chinese Japanese Germany Korea

Rosuvastatin calcium

Anti-hyperlipidemia drugs Pharmacological effects Pharmacokinetics Drug Interactions Synthesis pathways Indications Safety Side effects Uses
Rosuvastatin calcium
Rosuvastatin calcium structure
CAS No.
147098-20-2
Chemical Name:
Rosuvastatin calcium
Synonyms
ZD4522;Rostar;S 4522;CRESTOR;Fortius;ROSUVASTATIN CA;Rosuvastatin Calium;Rosuvastain Calcium;ROSUVASTATIN CALCIUM;ZD 4522, Calcium Salt
CBNumber:
CB9482678
Molecular Formula:
C44H54CaF2N6O12S2
Formula Weight:
1001.14
MOL File:
147098-20-2.mol

Rosuvastatin calcium Properties

Melting point:
122°C
alpha 
D24 +14.8° (c = 1.012 in 50% methanol)
storage temp. 
-20°C Freezer
form 
powder
color 
white to beige
optical activity
[α]/D +12 to +18°, c = 1 in methanol: water (1:1)
λmax
243nm(Phosphate buffer sol.)(lit.)
Merck 
14,8270
CAS DataBase Reference
147098-20-2(CAS DataBase Reference)

SAFETY

RTECS  MJ9675070
HS Code  29350090

Rosuvastatin calcium price More Price(5)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
TCI Chemical R0180 Rosuvastatin Calcium >95.0%(HPLC)(N) 147098-20-2 200mg $152 2018-11-22 Buy
Cayman Chemical 18813 Rosuvastatin (calcium salt) ≥98% 147098-20-2 10mg $25 2018-11-13 Buy
Cayman Chemical 18813 Rosuvastatin (calcium salt) ≥98% 147098-20-2 50mg $50 2018-11-13 Buy
Cayman Chemical 18813 Rosuvastatin (calcium salt) ≥98% 147098-20-2 100mg $88 2018-11-13 Buy
Cayman Chemical 18813 Rosuvastatin (calcium salt) ≥98% 147098-20-2 250mg $188 2018-11-13 Buy

Rosuvastatin calcium Chemical Properties,Uses,Production

Anti-hyperlipidemia drugs

Rosuvastatin calcium is an anti-hyperlipidemia drug which belongs to the inhibitor of HMG-CoA reductase successfully developed by the British AstraZeneca company. It is suitable for the treatment of various lipid abnormalities, including hypercholesterolemia, mixed lipid qualitative abnormalities and simple hypertriglyceridemia. Rosuvastatin calcium is listed as the strongest and the most comprehensive statins drugs which has entered into market for lipid-lowering and adjustment. Compared with atorvastatin which is currently recognized with the world's best efficacy, it has a better effect of lowering the level of LDL cholesterol and increasing the level of high-density lipoprotein. Moreover, it has a better tolerance, lower side effects and unique pharmacokinetic characteristics with the half-life about 20h. It only needs to be taken once a day.

Pharmacological effects

Rosuvastatin is a selective inhibitor of HMG-CoA reductase. HMG-CoA reductase inhibitor is the rate-limiting enzyme of the transition hydroxy-3-methylglutaryl coenzyme A to valerate A (The precursor of cholesterol). The main site of action of rosuvastatin is liver-the target organs of cholesterol-lowering. Rosuvastatin increases the number of hepatic LDL receptors on the cell surface, promoting the absorption and catabolism of LDL, inhibits hepatic synthesis of VLDL, thereby reducing the total number of VLDL and LDL particles.
For patients of homozygous and heterozygous familial hypercholesterolemia, non-familial hypercholesterolemia, and mixed dyslipidemia, Rosuvastatin can lower the total cholesterol, LDL-C levels, ApoB levels, non-HDL-C levels. Rosuvastatin also reduces the level of TG and increase the level of HDL-C. For patients of pure hypertriglyceridemia, rosuvastatin can lower total cholesterol, LDL-C, VLDL-C, ApoB, non-HDL-C, TG levels and increase the HDL-C levels.
Based on the general safety of pharmacology, repeated dose toxicity, potential genetic toxicity and the clinical information of carcinogenicity, no special toxicity was found for rosuvastatin on the human body. For studies on rat before and after birth, Rosuvastatin has obvious reproductive toxicity. It reduces the size, weight of the litter and birth rate. Treating female rats with a toxic dose which causes several times higher systemic exposure levels than the therapeutic exposure can enable the observation of these phenomena.
The above information is edited by the Chemicalbook of Dai Xiongfeng.

Pharmacokinetics

The drug can be absorbed in great amount by liver after oral administration with the volume of distribution at 134 L. After 3~5 hours, plasma concentration reaches the peak. The absolute bioavailability is around 20%. Plasma protein binding rate (mainly albumin) is about 90%. About 90% of the total dose of rosuvastatin is excreted by feces as prototype (including the absorption of the active substance and unabsorbed), with the rest excreted through the urine. 5% rosuvastatin in urine is in the form of prototype. Half-life of plasma elimination is about 19 hours. Elimination half-life doesn’t increase with increased dose. The geometric mean of plasma clearance rate is about 50L/hour (coefficient of variation 21.7%). Same as other HMG-CoA reductase inhibitors, the uptake of rosuvastatin by liver involves the participation of membrane transporter OATP-C. The transporter is important in the liver for the clearance of rosuvastatin.

Drug Interactions

1. Cyclosporine: when this product is used in combination with cyclosporine, the AUC of rosuvastatin is averagely 7 times higher than that observed in healthy volunteers (compared with the same dose using this service). Combination usage does not affect the plasma concentrations of cyclosporine.
2. Vitamin K antagonists: same as other HMG-CoA reductase inhibitor, for patients of simultaneously usage of vitamin K antagonists (such as warfarin), at the beginning or gradually increasing the dose of this product may cause the increase of INR (international normalized ratio). Stop using the product or gradually decreasing the dose can lead to decrease in INR. In this case, appropriate INR testing is needed.
3. Combination of gemfibrozil, fenofibrate, other fibrates and lipid-lowering doses (≥1g/day) of niacin with HMG-CoA reductase inhibitors can increase the risk of myopathy, which may be due to that they can cause myopathy when given alone.
4. Antacids: Mixing the product and one antacid containing aluminum hydroxide and magnesium for suspension can reduce the concentration of statin rosuvastatin plasma by 50%. Taking antacids two hours after taking this can further reduce the impact. The clinical significance of this drug interaction has not been studied.
5. Erythromycin: Combination with erythromycin can cause rosuvastatin AUC (0~t) decrease by 20% and Cmax decrease by 30%. This interaction may be due to the gastrointestinal motility caused by increase of erythromycin.
6. Oral administration of contraceptives/hormone replacement therapy (HRT): while using this drug together with oral contraceptives can cause the increase of ethinyl estradiol and norgestrel AUC by 26% and 34%, respectively. When choosing the dose of oral contraceptives, the patients should consider the increase of the plasma concentration of these drugs. Yet there are no pharmacokinetic data on taking rosuvastatin and HRT together. Therefore, we cannot exclude the presence of similar interactions. However, in clinical trials, this kind of combination is widely applied and can be well tolerated by patients.

Synthesis pathways

Synthesis pathways of Rosuvastatin calcium
Figure 1 Synthesis pathways of Rosuvastatin calcium

Indications

Primary Hypercholesterolemia: Usual dose of rosuvastatin calcium (10 mg) can significantly reduce LDLC levels in patients of primary hypercholesterolemia, and has a better efficacy compared with atorvastatin calcium (10mg). At the end of the experiment, TC, TG levels drop even more. Moreover, 5 mg of rosuvastatin calcium within the same eight weeks of treatment has a better effect on reducing LDLC level compared with 10 mg atorvastatin calcium. The difference is statistically significant, suggesting that the lipid-lowering effect of rosuvastatin calcium is better than that of atorvastatin calcium. Our experimental results are also consistent with the other previous assessment (STELLAR, MERCURY) about efficacy studies on statin drugs. Rosuvastatin calcium has a stronger LDLC-lowering effect than the other statins drugs (atorvastatin, simvastatin and pravastatin), allowing more patients to achieve recommended treatment goals.
Elderly coronary heart disease combined hyperlipidemia: Rosuvastatin calcium is capable of competitively inhibiting liver methylglutaryl coenzyme A reductase, and further exerts its good effect on reducing the fat. It has a long half-life. The gender and age of patients have no significant effect on the metabolism of drugs. The drug has only a few of adverse reactions. Meanwhile, the drug can also effectively promote the transport of low-density lipoprotein into cells, thus improving the cleaning effect of LDL, and playing a role in effectively lowering LDL. In addition, rosuvastatin calcium may also inhibit the aggregation of platelet, reduce the body's inflammatory response and protect their endothelial cells, effectively stabilize the plaque of patients suffering coronary artery disease to reduce its impact on the patient. The patients of experimental group in our hospital were treated with rosuvastatin calcium, which gives a significantly better lipid-lowering effect than patients in the control group, P <0.05, the difference was statistically significant. This further illustrates the usage of rosuvastatin calcium for treatment of elderly coronary heart disease combined hyperlipidemia has a good effect which can improve efficacy, reduce the blood fat with high clinical significance.

Safety

In terms of safety issue, the incidence of adverse cases for rosuvastatin calcium was similar to that of other related drugs. Adverse cases include elevated ALT, increased GGT and nausea.

Side effects

1. Adverse reactions of this product are generally mild and transient such as common headache, dizziness, constipation, nausea, abdominal pain, muscle pain and weakness.
2. For observed patients, the increase of creatine kinase (CK) levels is dose-related; the majority of cases were mild, asymptomatic and transient. Stop the treatment once the CK levels elevate (> 5 × ULN).
3. Impact on the liver: for a small number of patients, it was observed for a drug dose-related increase in transaminases; the majority of cases were mild, asymptomatic and transient.

Uses

For making lipid-lowering drugs.

Description

Rosuvastatin, one of the two new statins launched for the treatment of hypercholesterolemia, has high hepato-selectivity and more potent inhibitory effect on HMG-CoA reductase than the previously marketed statins. In rat hepatocytes, it inhibits cholesterol biosynthesis with an IC50 of 1.12 nM, which is ~100-fold higher potency than pravastatin. Rosuvastatin is synthesized in a 12-step sequence, entailing the construction of a pyrimidinyl aldehyde intermediate in eight steps and subsequent introduction of the dihydroxyheptenoate side chain via Wittig reaction with a bketophosphorane reagent and stereoselective carbonyl reduction of the resultant enone. Pharmacokinetic properties of rosuvastatin in humans, dosed at 5–80 mg, are approximately linear with dose. Following oral administration, rosuvastatin is rapidly absorbed with an oral bioavailability of ~20% and tmax of ~3 h. It has a prolonged duration of action, with terminal t1/2 of ~20 h, compatible with once-daily dosing. In humans, rosuvastatin is minimally metabolized through CYP2C9 and CYP2C19, with little or no metabolism via the CYP3A4. Approximately 90% of the administered oral dose is eliminated in the feces (92% as the parent compound) and the rest in the urine. Rosuvastatin is considered a “superstatin” due to its ability, at well-tolerated doses, to lower LDL cholesterol and triglycerides to a much greater extent than first generation statins. In patients with hypercholesterolemia, rosuvastatin treatment at doses of 5 and 10 mg/day over 12-week period resulted in 40–43% reduction of LDL-cholesterol levels, 12–13% increase in HDL-cholesterol, and 17– 19% reduction in triglycerides. In comparison, the efficacy range of LDL-cholesterol reductions by atorvastatin (10 mg/day), pravastatin (20 mg/day), and simvastatin (20 mg/day) was 28–35%. Rosuvastatin is a well-tolerated drug at doses of 1–20 mg and the most common side effects at these doses are headache, myalgia, pain and pharyngitis, which are consistent with those previously reported for statin therapy.

Chemical Properties

White to Off-White Crystalline Solid

Originator

Shinogi (Japan)

Uses

A selective, competitive HMG-CoA reductase inhibitor. Antilipemic.

Uses

antiinflammatory, glucocorticoid

Uses

antirheumatic

Definition

ChEBI: An organic calcium salt that is the hemicalcium salt of rosuvastatin.

brand name

Crestor (AstraZeneca).

Rosuvastatin calcium Preparation Products And Raw materials

Raw materials

Preparation Products


Rosuvastatin calcium Suppliers

Global( 356)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
Capot Chemical Co.,Ltd.
+86 (0)571-855 867 18
+86 (0)571-858 647 95 sales@capotchem.com China 19919 60
Shenzhen Sendi Biotechnology Co.Ltd.
0755-23311925 18102838259
0755-23311925 Abel@chembj.com CHINA 3203 55
Henan DaKen Chemical CO.,LTD.
+86-371-55531817
info@dakenchem.com CHINA 21930 58
Henan Tianfu Chemical Co.,Ltd.
0371-55170693
0371-55170693 info@tianfuchem.com CHINA 20680 55
Mainchem Co., Ltd.
+86-0592-6210733
+86-0592-6210733 sales@mainchem.com CHINA 32457 55
PI & PI BIOTECH INC.
020-81716320
020-81716319 Sales@pipitech.com CHINA 2543 55
Shanghai Yingrui Biopharma Co., Ltd.
+86-21-33585366 E-mail:sales03@shyrchem.com
+86-21-34979012 sales03@shyrchem.com CHINA 661 60
ATK CHEMICAL COMPANY LIMITED
+86 21 5161 9050/ 5187 7795
+86 21 5161 9052/ 5187 7796 ivan@atkchemical.com CHINA 24196 60
Xiamen AmoyChem Co., Ltd
+86 (0)592-605 1114
sales@amoychem.com CHINA 6374 58
career henan chemical co
+86-371-86658258
sales@coreychem.com CHINA 20516 58

View Lastest Price from Rosuvastatin calcium manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2018-07-26 Rosuvastatin calcium
147098-20-2
US $100.00 / KG 1KG 99% Customized career henan chemical co

147098-20-2(Rosuvastatin calcium)Related Search:


  • calcium (3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethan-3-ylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoate
  • ZD4522
  • (3R,5S,6E)-7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[N-methyl(n-methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-6-Hep
  • Rosuvastatin (as Ca salt)
  • Calcium (3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-y
  • ROSUVASTATIN, CALCIUM SALT
  • ROSUVASTATIN CALCIUM
  • ROSUVASTATIN CA
  • CRESTOR
  • (3R,5S,6E)-7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[N-methyl(n-methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-6-Heptenoic calcium
  • RosuvastatinCalcium&Z7,Z8,R3
  • 7-{4-(4-Fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoic acid
  • Rosuvastatin CalciuM (3R,5S,6E)-7-[4-(4-fluorophenyl)-6-(1-Methylethyl)-2-[N-Methyl(n-Methylsulfonyl)aMino]-5-pyriMidinyl]-3,5-dihydroxy-6-Heptenoic calciuM
  • Rosuvastatin Calium
  • Fortius
  • Rostar
  • Rosuvastatin hemicalcium
  • S 4522
  • ZD 4522, Calcium Salt
  • Rosuvastain Calcium
  • rosuvastatin Rosuvastatin CalciuM
  • (3R,5R,6E)-7-[4-(4-fluorophenyl)-2-(N-MethylMethanesulfonaMido)-6-(propan-2-yl)pyriMidin-5-yl]-3,5-dihydroxyhept-6-enoic acid
  • (+)-(3R,5S)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-(N-Methyl-N-MethanesulfonylaMino)pyriMidin-5-yl]-3,5-dihydroxy-6(E)-heptenoic acid calciuM salt (2:1)
  • Rosuvastatin calciuM(Crestor)
  • Rosuvastatin CalciuM (AMorphous)
  • Rosuvastatin CalciuM (ForM A)
  • 订购热线:17707567922(微信同号)
  • (+)-bis[7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3R,5S-dihydroxy-6(E)-heptenoic acid]calcium salt
  • -
  • C44H54F2N6O12S2Ca
  • C22H27FN3O6S12Ca
  • C22H28FN3O6SCa
  • 2C22H27FN3O6SCaC44H54CaF2
  • (3R,5S,6E)-7-{4-(4-Fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoic acid calcium salt
  • Rosuvastatin calcium Solution, 100ppm
  • Statins’Anti-Lipidemia Agents
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
  • Rosuvastatin
  • HMG-COA reductase, Hypolipidemic drugs
  • rosuvastatin calcium R
  • API
  • Aromatics
  • Chiral Reagents
  • Sulfur & Selenium Compounds
  • DERMATOP
  • 147098-20-2
  • 47098-20-2
  • C22H28FN3O6S12Ca
  • C44H54CaF2N6O12S
  • C22H27Ca05FN3O6S
  • C44H54CaF2N6O12S2
  • 2C22H27FN3O6SCaC44H54CaF2N6O12S2
  • Inhibitors
  • Active Pharmaceutical Ingredients
Copyright 2017 © ChemicalBook. All rights reserved